A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Who May Qualify: - Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening: - hypertension - dyslipidemia - obstructive sleep apnea, or - cardiovascular disease - Have a history of at least one unsuccessful dietary effort to lose body weight Who Should NOT Join This Trial: - Have type 1 diabetes, type 2 diabetes, or any other types of diabetes - Have an unstable body weight within 90 days prior to screening - Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening - Have acute or chronic hepatitis or pancreatitis - Are taking other medications or alternative remedies to manage weight loss Always talk to your doctor about whether this trial is right for you.